Shanghai, China, January 9, 2026 – ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ("ImmuneOnco", HKEX stock code: 01541.HK) announced that a three-person delegation from the company will attend the 44th Annual J.P. Morgan Healthcare Conference, where Dr. Wenzhi Tian, Founder, Chairman, CEO and CSO, will present a comprehensive overview of the company's development and key pipeline progress at Biotech Showcase™.

About timdarpacept (IMM01)

• CD47-targeted drug (SIRPα-Fc)

• Phase III interim data in 1L-CMML to be read out by year-end

• Phase III study in cHL selected for 2025 Pudong New Area High-Quality Industrial Development Special Program

• IND application submitted for cardiovascular disease (CVD)

About amulirafusp alfa (IMM0306)

• CD47×CD20 bispecific drug (mAb-Trap)

• Encouraging Phase II data in relapsed/refractory follicular lymphoma (ORR = 91.2%; CR = 67.6%)

• Patient enrollment initiated for Phase III registrational trial in R/R-FL

• Encouraging Phase Ib/II clinical trial data in SLE (IV infusion) (24-week SRI-4: 72.7% (8/11))

• Phase II IND approved for lupus nephritis (LN)

• Phase II/III IND application accepted for IgG4-RD

• Phase II IND application accepted for membranous nephropathy (MN)

• Phase Ib/II IND application accepted for SLE (subcutaneous injection)

About palverafusp alfa (IMM2510) / tazlestobart (IMM27M)

• IMM2510 is an ADCC-enhanced VEGF×PD-L1 bispecific antibody

• IMM27M is an ADCC-enhanced CTLA-4 antibody

• Encouraging preliminary clinical activity with IMM2510 + IMM27M combination

• In January 2026, ImmuneOnco regained global rights to IMM2510/IMM27M

About IMM72

• ActRIIA-Fc recombinant protein

• Unique differentiated advantages

• Indications include pulmonary arterial hypertension (PAH), left heart failure, osteoporosis

• Completed subject enrollment for single ascending dose (SAD) in Phase I clinical trial

• Initiating subject enrollment for multiple ascending dose (MAD)